NeuroQure's ASD Insight test empowers individuals and physicians with the first-of-its-kind autism risk test. Uncover the risk of autism starting as early as birth.
The average diagnosis occurs at 5 years of age, well past critical developmental windows. Traditional tools like the ADOS-2, while considered the "gold standard," face limitations in accessibility, cost, and suitability for children under 24 months or those with motor or sensory disabilities.
Detect autism signs as early as infancy
Enable early interventions for better outcomes
Gain peace of mind with our clinically proven technology
NeuroQure’s ASD Insight is a novel test that identifies autism risk within days of birth by detecting a molecular defect in IP3 channel gating through a functional skin biopsy assay. This breakthrough technology enables early detection and intervention, which research shows can lead to an average IQ improvement of over 17 points in toddlers with autism.
Up to 75% likelihood of predicting autism risk
Results available within weeks sample collection
Suitable for those as young as two days old
A recent study published in PubMed highlights the critical role of rare inherited genetic variants in contributing to autism risk. Unlike common genetic variations, these rare variants often passed down from parents, can significantly impact neurodevelopment, influencing the likelihood of an ASD diagnosis. Researchers aim to improve early detection and intervention strategies for families at risk by better understanding these inherited genetic factors.
A groundbreaking study reveals that individuals with ASD exhibit distinct metabolic profiles. Using advanced metabolomics analysis, researchers identified significant differences in key metabolic pathways, such as amino acid and lipid metabolism. These findings pave the way for innovative diagnostic tools and therapeutic approaches, offering new insights into the biological underpinnings of ASD.
Since science has proven that autism is treatable through effective therapies*, the earlier treatment begins, the better the outcome for the child.
At NeuroQure, we're empowering people with children and physicians alike to transform lives. How? By receiving an accurate diagnosis of risk within days of a skin sample.
The Average Age of Diagnosis is 5 Years Old
41% in life-long services cost savings
Apply for qualifying services with traditionally long wait times
Plan ahead for living arrangements, schools, insurance, and more
Get answers today.